The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
£600k in sales to USA in period from zero in last comparable period. Companies in US responding to Inflation Reduction Act and China restrictions?
Also company structuring £6m convertable debt for working cap and Madagascar expansion (see end of report). Debt funding essential at this stage imho.
Thx Anon.
Very professional presentation.
They were excited for Kertang. 3D cost £25m already sunk. Worth half for our share.
Could drill 2025 after farm down in 1H 2024.
Tax rebate received.
Anyone estimate current cash?
Current £10m mcap seems very low even in bear market?
The web site messages are unambiguous in that funds are already in escrow account and we have a completion date. Previous info gives amount received and number of shares in issue. I find it hard to believe its true but what possible motive could there be for anyone to put false information on company website?
Great research Myles. Your conclusions seem spot on to me. I think the TSG situation has weighed heavily on us particularly as the downstream possibilities were regularly promoted by the company. The valuation metrics would support us as an upstream producer alone.
Regarding the cost per mt, which has increased from £241 to £454 per mt. Normally with economies of scale you would expect this to drop. This suggests a lot of capital spending has been disallowed by auditors and has hit the current year as revenue expenditure. If we say, assume less of this to year end then I could see cost at say £300 per mt. If we hit 6000 mt production and sell all at £689 then we could hit ebitda of over £2m and operating profit of around £1m assuming modest increase in expenses. Anybody else got thoughts on next 6 months?
Just seen the news. Can’t believe it but why raise our hopes. Surely nothing to gain from ctag.
Does anyone know whether shares were reorganised or anything after delisting and off market fund raises.
Was on the trail and have now subscribed for the product. For information I had initial good results and then plateaued a bit. After 6 weeks scaling on my knees improved dramatically and I have not used a steroid cream for 2 months. I had been using creams for around 40 years and on your knees it spoils your trousers and bedding as other sufferers will know. So all good for me and will add as funds come available.
Sales may be a slow burner and we may have to be patient but it does work for me.
The family have shown their ambition with IPO and then seeking OTC listing. Going private would limit them to organic growth. They are not going to cut off access to capital at this stage and even a 30% stake would ensure effective control. They are in for the long game in my opinion. Value will out in the medium term. All imho.
Hi J
The way I understand it we pay approx £10m for the assets and IP of Tsg including graphene tech. We also pay around £6m in terms of warrants (sp-40p) by year end. So we have approx an extra 16m shares dilution to set off against value of Tsg. Is TSG worth £16m? I think it is, so will top up if it goes towards 90p. DYOR of course.
Have done the research here and this looks such a good company in the making. Looking at SP keep thinking I must have missed something and would appreciate any insights. Could it be mistrust in mgt not being UK based or worries over approvals of downstream merger?
Trade and other receivables would be invoiced amounts not yet received at bs date i.e. 31st May. For sales you have to add amounts already received plus June invoices